Centogene

• Public Offering of Primary and Secondary shares on Nasdaq, raising in total USD 49.0 million through the placement of 3,500,000 common shares at a price per share of USD 14.00, excluding the exercise of the over-allotment option
• The Primary Offering, for which proceeds will go to the Company, raised USD 28.0 million by placing a total of 2,000,000 common shares, and the Secondary Offering, for which proceeds will go to the selling shareholders, raised USD 21.0 million by placing 1,500,000 common shares. The selling shareholders (historical founders, executives and pre-IPO investors) continue to hold a substantial shareholding in the Company
• The transaction represents a sizeable liquidity event for the Company, which completed its USD 56.0 million IPO on Nasdaq in November 2019
• Proceeds from the Primary Offering will be used for R&D to support orphan drug development with Centogene’s knowledge-driven information platform, as well as for working capital and other general corporate purposes
• Kempen & Co was keen to work with Centogene given its unique position in the use of genetic data and artificial intelligence, an emerging focus area for Kempen & Co’s Life Sciences & Healthcare franchise
• In 2020 year to date, Kempen & Co has executed 14 transactions for European Life Sciences companies, including 5 transactions for Nasdaq listed companies

Centogene is a commercial-stage company focused on rare diseases, transforming real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. Centogene aims to bring rationality to treatment decisions and accelerate the development of new orphan drugs by using extensive knowledge of rare diseases, including epidemiological and clinical data, as well as innovative biomarkers. Centogene has developed a global proprietary rare disease platform based on their real-world data repository with c. 3.0 billion weighted data points from over 530,000 patients in more than 120 countries. The platform includes multi-omic data (e.g. epidemiologic, phenotypic, proteomic, metabolomic and genetic data) that reflects a global population, and also a biobank of these patients' blood samples.

Over the past year, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma 
• Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
• Co-Manager in the USD 600 million US Public Offering by Ascendis Pharma
• Financial advisor in the USD 253 million Immatics’ business combination with Arya Sciences Acquisition Corp.Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
• Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
• Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
• Co-Manager in the USD 862 million Global Offering by argenx
• Joint Bookrunner in the SEK 1,414 million Capital Increase by Oncopeptides
• Co-Manager in the USD 154 million Global Offering of DBV Therapeutics
• Joint Global Coordinator and Joint Bookrunner in the €19.0 million Capital Increase by Sequana Medical
• Lead Manager in the USD 557 million Global Offering by argenx
• Co-Manager in the USD 79.2 million US Public Offering by Merus
• Co-Manager in the USD 57.5 million Capital Increase by ProQR
• Co-Manager in the USD 150 million Nasdaq IPO of BioNTech
• Sole Bookrunner in the €9.0 million Capital Increase by MDxHealth
• Co-Manager in the USD 20.0 million Global Offering of Celyad
• Co-Manager in the USD 582 million NASDAQ IPO of Genmab